Royalty Pharma plc (NASDAQ: RPRX) has a price-to-earnings ratio of 11.09x that is above its average ratio. Additionally, the 36-month beta value for RPRX is 0.47. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RPRX is 379.38M and currently, short sellers hold a 3.73% ratio of that float. The average trading volume of RPRX on April 30, 2024 was 2.80M shares.
RPRX) stock’s latest price update
Royalty Pharma plc (NASDAQ: RPRX)’s stock price has increased by 0.43 compared to its previous closing price of 28.00. However, the company has seen a 1.08% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-19 that NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
RPRX’s Market Performance
RPRX’s stock has risen by 1.08% in the past week, with a monthly drop of -7.41% and a quarterly drop of -3.20%. The volatility ratio for the week is 1.84% while the volatility levels for the last 30 days are 2.23% for Royalty Pharma plc The simple moving average for the last 20 days is -1.48% for RPRX stock, with a simple moving average of -2.33% for the last 200 days.
Analysts’ Opinion of RPRX
Many brokerage firms have already submitted their reports for RPRX stocks, with UBS repeating the rating for RPRX by listing it as a “Buy.” The predicted price for RPRX in the upcoming period, according to UBS is $47 based on the research report published on June 14, 2022 of the previous year 2022.
Scotiabank, on the other hand, stated in their research note that they expect to see RPRX reach a price target of $53. The rating they have provided for RPRX stocks is “Sector Outperform” according to the report published on May 13th, 2022.
Goldman gave a rating of “Buy” to RPRX, setting the target price at $56 in the report published on April 27th of the previous year.
RPRX Trading at -5.02% from the 50-Day Moving Average
After a stumble in the market that brought RPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.36% of loss for the given period.
Volatility was left at 2.23%, however, over the last 30 days, the volatility rate increased by 1.84%, as shares sank -5.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.36% lower at present.
During the last 5 trading sessions, RPRX rose by +1.08%, which changed the moving average for the period of 200-days by -8.43% in comparison to the 20-day moving average, which settled at $28.45. In addition, Royalty Pharma plc saw 0.11% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RPRX starting from RIGGS RORY B, who sale 35,702 shares at the price of $27.55 back on Jan 04 ’24. After this action, RIGGS RORY B now owns 20,099 shares of Royalty Pharma plc, valued at $983,504 using the latest closing price.
RIGGS RORY B, the Director of Royalty Pharma plc, sale 199,098 shares at $27.79 during a trade that took place back on Jan 03 ’24, which means that RIGGS RORY B is holding 55,801 shares at $5,532,276 based on the most recent closing price.
Stock Fundamentals for RPRX
Current profitability levels for the company are sitting at:
- 0.63 for the present operating margin
- 0.7 for the gross margin
The net margin for Royalty Pharma plc stands at 0.48. The total capital return value is set at 0.09. Equity return is now at value 18.68, with 6.84 for asset returns.
Based on Royalty Pharma plc (RPRX), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at 0.49. The debt to equity ratio resting at 0.94. The interest coverage ratio of the stock is 7.98.
Currently, EBITDA for the company is 1.49 billion with net debt to EBITDA at 3.57. When we switch over and look at the enterprise to sales, we see a ratio of 7.74. The receivables turnover for the company is 3.04for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.90.
Conclusion
In conclusion, Royalty Pharma plc (RPRX) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
